Steroid-associated osteonecrosis (SAON) is one of the common complications of clinical glucocorticoid (GC) administration, with osteocyte apoptosis appearing as the primary histopathological lesion. However, the precise mechanism underlying SAON remains unknown. Epigenetic modification may be a major cause of SAON. Recently, cumulative research revealed that Ten-Eleven Translocation (TET) proteins can catalyze the conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) and then alter the epigenetic state of DNA. Here, we report that TET3-5hmC was up-regulated in the femoral head tissues of SAON patients and MLO-Y4 cells with dexamethasone (Dex) treatment. Knockdown of TET3 in MLO-Y4 cells decreased 5hmC enrichment and rescued Dex-induced apoptosis. Meanwhile, the local intramedullary injection of TET3 siRNA in Sprague-Dawley rats abrogated GC-induced osteocyte apoptosis, histopathological changes, abnormal MRI signals and bone microstructure declines in the femoral head in vivo. Moreover, a hydroxymethylated DNA immunoprecipitation (hMeDIP)-chip analysis of Dex-treated osteocytes revealed 456 different 5hmC-enriched genes. The Akt pathway was found to mediate the functional effect of Dex-induced dynamic 5hmC change; this was further verified in clinical samples. The loss of TET3 in MLO-Y4 cells abrogated Dex-induced Akt signaling pathway inhibition. Therefore, our data for the first time identify the effect of TET3-5hmC on the Akt pathway and the necessity of this signaling cascade in SAON, identifying a new potential therapeutic target. This article is protected by copyright. All rights reserved
Introduction
SAON is considered a multifactorial disease that leads to subchondral collapses and total joint replacement during later stages (1, 2) . SAON ranks first among the known risk factors of nontraumatic femoral head necrosis, which is associated with the wide use of glucocorticoids (GCs) to treat many diseases in the clinic (e.g., rheumatoid arthritis and systemic lupus erythematosus) (3) .
There are several alternative mechanisms underlying SAON, such as fat embolization, intramedullary pressure changes, modified artery constriction, circulatory impairment, coagulation disorders and cell dysfunction (4, 5) . However, osteocyte apoptosis has recently been shown to be the primary histopathological change in osteonecrosis (1, (6) (7) (8) . GCs induce osteocyte apoptosis, which disrupts the mechanosensory function of the osteocyte lacunar-canalicular system and ultimately leads to the collapse of the femoral head (1) , but the molecular mechanism of osteocyte apoptosis remains elusive.
Epigenetics, an effective method for studying the interplay between environmental signals and the genome, has received a great deal of attention recently (9) . It is becoming apparent that methylation modification plays an important role in SAON. Aberrant methylation of the ABCB1 gene has been shown to be responsible for the pathogenesis of SAON (4) , and icariin may benefit the mesenchymal stem cells of patients with SAON through ABCB1 promoter demethylation (10) .
However, in the past few years, it has become apparent that DNA methylation is not a static epigenetic mark but is highly dynamic and is governed by a precise molecular network of regulators (11) . 5mC can be further oxidized to 5hmC, 5-formylcytosines (5fC) and 5-carboxylcytosines (5caC) by the TET protein family including TET1, TET2 and TET3, resulting in active demethylation (12, 13) . The dysregulation of 5hmC levels may lead to neurological diseases, This article is protected by copyright. All rights reserved 4 cancer, arthritis and some other diseases (14) .
In view of the recent advances in the understanding of DNA demethylation pathways and increasing evidence of the function of stable 5hmC and its derivatives in the epigenome, we sought to investigate the effect of TET and 5hmC in SAON. In this study, we therefore first measured the expression of TET1, TET2, TET3 and 5hmC in bone tissues from SAON and femoral neck fracture patients. Then, we examined the changes in 5hmC and the TET family in Dex-treated MLO-Y4 cells. A hMeDIP-chip analysis was performed to explore the functional effects of dynamic 5hmC change, which were further studied in clinical samples. Knockdown of TET in MLO-Y4 cells or in vivo siRNA technology were used to verify the effect of TET-5hmC on Dex-induced osteocyte apoptosis and SAON. We aimed to determine the effects of GCs on the epigenome of osteocyte and define the role of TET-5hmC in a SAON model. The severity of SAON and femoral neck fracture was evaluated using the Ficat and Garden staging system, respectively (15, 16) . SAON operative indications included a collapsed necrotic femoral head with intractable pain. Patients with a demonstrable history of direct trauma or with the possibility of a combination of causes were excluded (17) . During surgery, the femoral head was extracted and then the necrotic bone around the center of femoral head was harvested for study. Bone specimens from This article is protected by copyright. All rights reserved 5 6 patients who underwent hip arthroplasty for femoral neck fractures were harvested from the same place and used as controls. No age-matched controls could be obtained because of the absence of a surgical indication for hip arthroplasty in young patients with femoral neck fractures.
Cell cultures, Dex treatment and transfection
MLO-Y4 osteocyte-like cells (a gift from Dr. Lynda Bonewald, University of Missouri-Kansas City) were cultured as previously described (18) . For dose-dependent experiments, cells were treated with varying concentrations (10 -8 M to 10 -5 M) of Dex (Sigma-Aldrich, USA). For time-dependent experiments, cells were treated with 10 -6 M Dex for various durations of time (19, 20) . To activate the Akt signaling pathway, cells were exposed to the PTEN inhibitor bpV(phen) (10 -6 M, Sigma-Aldrich) for 30 min. Afterwards, the cells were incubated with 10 -6 M Dex for up to 12 h.
For knockdown of TET, TET1 specific siRNA (TET1-1 GCAGATGGCCGTGACACAAAT, TET1-2 GCAGCTAGCTATAGAGTATAG), TET2 specific siRNA (TET2-1 CTCAGGGATGTCCTATTGCTAAA, TET2-2 GGATGTAAGTTTGCCAGAAGC), TET3 specific siRNA (TET3-1 GCTCCAACGAGAAGCTATTTG, TET3-2 AAGCGCAACCTATTCTTGGAA) and control scramble siRNA (ACGUGACACGUUCGGAGAATT) were synthesized by Biotend (Biotend Biotechnology Co., Ltd, China) based on published studies (21) . Transfections were performed using Lipofectamine 2000 Transfection Reagent (Invitrogen, USA) according to the manufacturer's protocol. Twenty-four hours thereafter, cells were treated with 10 -6 M Dex for an additional 12 h.
hMeDIP-chip and data processing
MLO-Y4 cells were treated with 10 -6 M Dex for 0 h, 4 h and 12 h. Thereafter, genomic DNA (gDNA) was extracted and sonicated to random fragments of 200-1000 bp. One microgram of sonicated gDNA was immunoprecipitated with 1 μl of 5hmC antibody overnight at 4°C with This article is protected by copyright. All rights reserved 6 rocking agitation. Then, antibody-DNA complexes were captured with protein A/G beads (ThermoFisher Scientific, USA). Then, 5hmC-containing DNA fragments were purified using Qiagen MinElute columns (Qiagen, Germany). For DNA labeling, the NimbleGen Dual-Color DNA Labeling Kit was used according to the manufacturer's guidelines (Nimblegen, USA), and the labeled DNA was purified using isopropanol/ethanol precipitation. A mouse RefSeq Promoter Array (Arraystar lnc, Rockville, USA) was hybridized with the labeled DNA at 42°C for 16 to 20 h in a hybridization chamber (Nimblegen) (22) .
The hMeDIP chip data were analyzed with NimbleScan v2.5 (NimbleGen). A normalized peakMvalue (peakMvalue=log 2 hMeDIP/Input) was created for each sample to quantify the relative value of 5hmC, which is proportional to 5hmC expression. The threshold set of peakMvalue changes≥0 represented the different 5hmC-enriched genes (DEG). KEGG pathway and GO analysis of DEG were performed using the database for annotation, visualization and integrated discovery (DAVID) website (23) . The -log 10 (pValue) was used as a measure of the significance of the pathway associated with the 5hmC change. A heat map and Venn diagram showing the dynamic change in 5hmC were constructed with MultiExperiment Viewer v4.9 and Venny 2.1 website, respectively.
Establishment of the SAON model and knockdown of TET3 in vivo
The animal procedures were conducted according to the Guide for the Care and Use of Laboratory Animals: Eighth Edition, and the study protocol was approved by the Ethical Committee of the Tianjin Medical University General Hospital and Tianjin Hospital.
Twenty-four 3-month-old adult male weight-matched Sprague Dawley (SD) rats (203±14 g) were randomly divided into 4 experimental groups of 6 rats each and kept under the same standard conditions; water and food were available ad libitum.
The SAON model was established based on a protocol reported previously (24) ; This article is protected by copyright. All rights reserved 7 methylprednisolone sodium (MPS, Pharmacia & Upjohn, Peapack, USA) was subcutaneously injected at a dose of 21 mg/kg per day for 4 weeks. The siRNA transfection complex was prepared according to the manufacturer's instructions. Briefly, 5 nmol siRNA (Biotend), 40 μl Entranster-in vivo transfection reagent (Engreen, China), and 40 μl of 10% glucose were mixed for 15 mins at room temperature. TET3 or scramble siRNA-Entranster-in vivo complex was injected into medullary cavity of bilateral distal femur twice over the course of 4 weeks (2, 25, 26) . Euthanasia was performed at week 4. The left femoral heads were used for Micro-CT scan (n=6/group), histological evaluation (n=6/group) and TUNEL analysis (n=6/group) (27, 28) . The right femoral heads were separated into two parts for western blot (n=4/group) and dot blot analysis (n=4/group).
Micro-CT-based trabecular architecture assessment
The femoral heads were scanned with an Inveon micro PET/CT manufactured by Siemens (Berlin, Germany) at a voltage of 80 kV and a current of 500 μA, with an entire scan length of 20 mm from the top of the femoral head to the femoral shaft in a spatial resolution of 10 μm. 3-D structures were reconstructed using the Inveon analysis workstation. The ROI was determined as an irregular anatomic contour adjacent to the endocortical surface and epiphyseal line in proximal epiphysis.
The cortical bone and spongy bone were separated manually by auto trace; later, the trabeculae and the bone marrow were separated using the threshold function (29) . The bone volume/total volume (BV/TV), bone surface area/bone volume (BS/BV), trabecular thickness, trabecular number, trabecular separation were calculated (30) .
Statistical analysis
Osteonecrosis was defined as previously described and the incidence of SAON in rats was defined as the number of femoral heads with predominant empty lacunae divided by 6 femoral heads in each group (27, 28) . Number data were expressed as the mean ± SD with ANOVA (Fisher's least This article is protected by copyright. All rights reserved 8 significant difference, LSD) method to assess significant differences between groups. Analysis of covariance (ANCOVA) was used to correct the age bias between SAON and fracture patients. All experiments were repeated at least three times. Statistical analysis was performed using SPSS 20.0 software (Chicago, USA). p<0.05 was considered significant.
Results

TET3-5hmC level was up-regulated in SAON femoral heads.
The patient characteristics are listed in Supplemental tables 1 and 2. In the SAON group, 6 SAON patients ranging from 59 to 77 years old (66.2±6.6 years) were enrolled. In the control group, 6 patients ranging from 68 to 85 years old (76.2±5.5 years) were included. The representative radiographs showed prominent femoral head erosion and collapse in the SAON group and evident femoral neck fracture in the control group ( Figure 1A ). TUNEL analysis was performed to measure cell apoptosis in the bone tissues. In the SAON group, osteocytes embedded in the trabecula displayed strong TUNEL staining, which is consistent with previous studies ( Figure 1B , 1C) (31) . It has been reported that TET3 mediates GC-induced harmful neurodevelopmental effects (32) . To explore the role of TET in the pathogenesis of SAON, TET1, TET2 and TET3 levels were analyzed.
Real-time PCR showed that the levels of TET1 and TET2 were unchanged, while the expression of TET3 was increased in SAON tissues ( Figure 1D-1F ), which was confirmed by western blot ( Figure 1G, 1H ). TET3 mediates 5mC conversion to 5hmC, 5fC, and 5caC. As the steady-state level of 5hmC is considered much higher than the pool of 5fC and 5caC (33) , we evaluated only the 5hmC level. DNA dot blot indicated strong enrichment of 5hmC in SAON ( Figure 1I , 1J).
The TET3-5hmC increase was involved in Dex-induced osteocyte apoptosis.
To determine the effect of GC treatment on osteocyte viability, we first performed an in vitro
cells. A TUNEL assay indicated that MLO-Y4 cells treated with Dex
This article is protected by copyright. All rights reserved 9 demonstrated a dose-dependent increase in apoptosis (Figure 2A, 2B ). Furthermore, MLO-Y4 cells treated with a time course of 10 -6 M Dex (a range from 2 h, 4 h, 8 h to 12 h) showed increased apoptosis ( Figure 2C , 2D). To explore the mechanism of Dex-induced apoptosis, Bcl-2, Bax and cleaved caspase-3 protein levels were quantified. The data showed that pro-apoptotic Bax and cleaved caspase-3 were up-regulated, while the anti-apoptotic Bcl-2 protein level was lower at 8 h and 12 h ( Figure 2F ). In the CCK-8 and trypan blue exclusion assay, the number of MLO-Y4 normal cells was found to be reduced by Dex treatment in both a dose-dependent and a time-dependent manner (Supplemental Figure 1A , 1B, 2A, 2B). In addition, an ethynyl deoxyuridine (EdU) incorporation assay indicated that DNA replication and cell proliferation were suppressed by Dex (Supplemental Figure 1C , 1D, 2C, 2D).
To study whether TET and 5hmC were involved in Dex-induced apoptosis in vitro, genome-wide 5hmC levels and the expression of TET1, TET2 and TET3 were quantified. IF and dot blot showed that global 5hmC was up-regulated by Dex in a time-dependent manner (Figure 2E, 2G ). Real-time PCR revealed that TET3 increased after Dex treatment while TET2 remained unchanged. Although TET1 increased slightly, it was not as significant as TET3 ( Figure 2H -2J), which was similar to the results of the protein expression analysis ( Figure 2K ). The up-regulation was observed in both total and nuclear TET3, as revealed by subcellular extraction analysis ( Figure 2L ). These data indicated that TET3 may localize in nucleus after Dex treatment to induce 5hmC enrichment and initiate osteocyte apoptosis.
The Akt pathway mediated the functional effect of Dex-induced dynamic changes in 5hmC.
To understand the functional effect of the 5hmC change, we performed a hMeDIP-chip assay to examine the 5hmC epigenome in MLO-Y4 cells over the course of Dex treatment. Following the hMeDIP-chip assay and purification of 5hmC-enriched DNA fragments, the ArrayStar Mouse This article is protected by copyright. All rights reserved 10 RefSeq Promoter Array was used to characterize the distribution of 5hmC within promoters. A heat map and Venn diagrams were used to depict the dynamic change in Dex-induced 5hmC expression. Four hundred fifty-six genes predicted to have different enrichment levels of 5hmC were selected. Of these genes, 92 genes were 5hmC-upregulated and 98 genes were 5hmC-downregulated in all Dex-treated MLO-Y4 cells (4 h and 12 h). Moreover, 122 5hmC-upregulated genes and 144 5hmC-downregulated genes occurring in Dex treatment for 12 h were also identified ( Figure 3A ).
Then, we used Venn diagrams to further show the dynamic 5hmC change in different types of genes.
The genes were classified as high CpG genes (HCG), intermediate CpG genes (ICG) and low CpG genes (LCG) based on the CpG content in the promoter. The number of genes with differential 5hmC enrichment is listed in Figure 3B . GO analysis revealed significant accumulation of DEG involved in several important cellular processes, such as development, localization, metabolism and differentiation ( Figure 3C ).
KEGG pathway analysis showed that signaling pathways, including the PI3K-Akt pathway, Notch pathway, apoptosis pathway and Wnt pathway, exhibited dynamic changes in 5hmC levels ( Figure 4A , 4B). The PI3K-Akt and Notch are signaling pathways showed the most significant 5hmC up-regulation and down-regulation, respectively. Eleven genes associated with the PI3K-Akt signaling pathway and the corresponding peakMvalues are listed in table 1, which shows the 5hmC expression in these gene promoters. Then, we used real-time PCR to quantify the mRNA expression of these genes. The results showed that PTEN, Ppp2r5d and JAK3 were up-regulated with different patterns in Dex-treated cells relative to control cells, while PIK3r5, PIK3cd, TCL1 and PDK2 were down-regulated ( Figure 4C down-regulated in all Dex-treated cells. Meanwhile, the total Akt level did not change significantly ( Figure 4N ). To further explore whether the Akt pathway mediates the functional effect of Dex-induced 5hmC change, bpV(phen) was used to activate the Akt pathway. We found that the osteocyte apoptosis induced by Dex was reversed significantly by activating Akt signaling, and western blot revealed the same pattern ( Figure 5A-5C ). Significantly, the levels of Akt and apoptosis were also changed in SAON tissues. The expression of PTEN was increased in SAON, while p-Akt and p-PI3K decreased. Meanwhile, Bcl-2 decreased at the protein level in SAON, but Bax and active caspase-3 increased ( Figure 5D ). These data verified that the PTEN-Akt pathway mediates the functional effect of Dex-induced TET-5hmC change in osteocyte and is critical for osteocyte apoptosis and SAON.
Additionally, we also found changes in Notch4 (not Notch2) expression in SAON tissues (Supplemental Figure 3) . Thus, Notch signaling may also partially mediate the functional effect of 5hmC change and could be further explored in the future.
Knockdown of TET3 abrogated Dex-induced osteocyte apoptosis and Akt pathway inhibition.
To further confirm the effect of TET-5hmC on Dex-induced osteocyte apoptosis, we performed siRNA-mediated knockdown of TET1-3 expression in MLO-Y4 cells. We first tested the efficacy of several reported TET1-3 sequences in knocking down TET expression. After 24 h of transfection, real-time PCR data showed that five sequences (siTET1-1, siTET2-1, siTET2-2, siTET3-1 and siTET3-2) decreased TET mRNA expression ( Figure 6A ). The cells transfected with siTET1-1, siTET2-2 and siTET3-1 were used in the subsequent experiments. Significantly, only knockdown of TET3 reversed Dex-induced apoptosis, while knockdown of TET1 or TET2 had no effect ( Figure   6B ). Twelve hours After Dex treatment, 30.00±1.91% of transfected control cells, 30.05±2.47% of siTET1-transfected cells, and 30.75±3.46% of siTET2-transfected cells were TUNEL positive. In contrast, the number of apoptotic cells decreased to 17.14±1.06% in siTET3-transfected cells ( Figure 6C ). Western blot indicated that only knockdown of TET3 inhibited caspase-3 activation, although knockdown of TET1 and TET2 had a slight effect on Bcl-2 ( Figure 6D ). In addition, transfection of siTET3 reversed Dex-induced TET3 up-regulation at the protein level. Subcellular extraction analysis indicated that nuclear TET3 was also down-regulated ( Figure 6E , Supplemental Figure 4A ). Meanwhile, dot blot and IF showed that the global enrichment of 5hmC was abrogated after knockdown of TET3 ( Figure 6F, 6G) . These results further verified that TET3 is specific and indispensable for Dex-induced 5hmC enrichment and osteocyte apoptosis.
We further explored the activity of the Akt signaling pathway. Compared with the Dex-treated group, knockdown of TET3 reversed the phosphorylation of Akt and down-regulated PTEN levels;
thus, the suppression of the Akt signaling pathway decreased ( Figure 6H ).
The data showed that the number of normal MLO-Y4 cells in the siTET3 group was larger than that in the Dex-treated group (Supplemental Figure 4B, 4C ). Further EdU incorporation assays showed that the number of EdU positive cells increased significantly after TET3 knockdown compared with Dex treatment (Supplemental Figure 4D, 4E ).
Knockdown of TET3 alleviated SAON in vivo
TET3 siRNA transfection in vivo was performed as illustrated in Figure 7A . Western blot showed that siTET3 treatment, which did not alter the levels of TET1 and TET2, abrogated MPS-induced TET3 expression in femoral head bone tissues ( Figure 7B ) and further reversed MPS induction of global 5hmC accumulation ( Figure 7C ). We next explored the therapeutic effect of TET3 knockdown on SAON by performing HE staining, TUNEL assay, Micro-CT and MRI scans in rats. HE staining showed obvious empty bone lacunae and adipocytes in the bone marrow of the SAON group; these effects were rescued by This article is protected by copyright. All rights reserved 13 siTET3 treatment. The incidence of osteonecrosis at week 4 was 83.3% (5/6) in the SAON group and 0 (0/6) in the siTET3 group by the standard of HE stained histological examination ( Figure 7D ). TUNEL analysis showed that the osteocytes embedded in the trabeculae at the proximal epiphysis of the femoral head displayed intense staining in the SAON group, while few osteocytes displayed positive staining with siTET3 treatment (Figure 7E, 7F) .
Micro-CT showed that MPS treatment decreased the BV/TV, trabecular number and trabecular thickness and increased trabecular separation, indicating apparent trabecular bone loss in SAON femoral heads; this change was significantly rescued by siTET3 treatment (Figure 7G, 7H) .
Moreover, MRI scans showed heterogeneous T 1 W 1 signals and high-intensity T 2 W 1 signals in the femoral head in the SAON and scramble groups. In contrast, the siTET3 group showed a homogeneous T 1 W 1 signal and a low-intensity T 2 W 1 signal, similar to the results observed in a normal femoral head ( Figure 7I ). Collectively, these data suggest that knockdown of TET3 alleviated osteocyte apoptosis and SAON in vivo.
Discussion
Our results uncovered a direct impact of the TET3-5hmC-Akt pathway on the pathogenesis of SAON (Figure 8 ). This deduction is based on the following. First, we observed that a global enrichment of 5hmC and TET3 increase in SAON bone specimens. Second, we found that hydroxymethylation in neural stem cells, with TET3 being a key factor for harmful neurodevelopmental effects (32) , thereby implicating alterations in the TET3-5hmC pathway in SAON.
The pattern of DNA methylation at cytosine bases in the genome is tightly linked to gene expression, and DNA methylation abnormalities are often observed in diseases. The TET proteins promote the reversal of DNA methylation (33) . TET1 is indispensable for maintaining embryonic stem cell pluripotency and exerts tumor suppressing functions in gastric cancer (34, 35) . TET2 was positively correlated with the regulation of neuron survival (36) . TET3 is required for the normal survival, proliferation and differentiation of neural progenitor cells (32) . Nevertheless, the expression pattern and exact function of these three important proteins have not been reported in bone tissues previously. In our study, we first found the expression of TET1, TET2 and TET3 in bone tissues.
TET3 function appears to be distinct from that of TET1 and TET2 in SAON pathogenesis, as our data showed that only TET3 expression was significantly up-regulated and accompanied by 5hmC accumulation in SAON. TET1 was also slightly increased by Dex treatment in vitro, but not as obviously as TET3. In addition, only knockdown of TET3 could reverse Dex-induced MLO-Y4 cell apoptosis; thus, TET3 is specifically involved in Dex-induced osteocyte apoptosis and SAON.
Apart from a conserved core catalytic region in the C terminus of each TET protein, TET1 and TET3 have an N-terminal CXXC zinc finger domain that can bind DNA and facilitate recruitment to target genes in the genome (37, 38) . Thus, GC-induced TET, especially TET3 expression, may aid in the demethylation of target genes. In addition to enzymatic roles, TET proteins serve as transcriptional co-activators/co-repressors by interacting with some transcriptional regulators and scaffolding proteins (39) . Further studies are needed to clarify the effects of such non-enzymatic activity of TET proteins induced by GCs.
GCs, including cortisol as the predominant GC in human, regulate the expression of a wide array of target genes through binding to glucocorticoid receptor α (GRα) and GRβ. Both are members of the nuclear receptor superfamily and present in osteocytes (40, 41) . GCs lead to multiple changes of osteocytes; however, studies regarding the roles of GRs in mediating these effects are scarce (41) . It has been reported that GRs mediate GC promotion of osteocyte apoptosis by activating Pyk2 and JNK, followed by inside-out signaling that leads to anoikis (42) . Our demonstration that GCs induce osteocyte apoptosis is consistent with previous studies (18, (43) (44) (45) . We found that GCs induced TET3 up-regulation and localization to the nucleus, as well as 5hmC enrichment in a time-dependent manner, in osteocytes. Thus, it is suspected that GRs have the potential to mediate the expression of TET3, initiate genomic hydroxymethylation and osteocyte apoptosis. However, how TET3 is modulated by GRs and recruited into the nucleus to modify methylation needs to be further studied.
A hMeDIP-chip assay was performed to understand the functional effect of 5hmC enrichment.
The dynamic changes in 5hmC distribution with Dex treatment are similar to the 5hmC distribution in progenitor differentiation during chondrogenesis and neurogenesis (12, 21) . KEGG pathway analysis indicated that the PI3K-Akt signaling pathway could mediate the functional effect of Dex-induced 5hmC change, a finding that was verified when the pharmacological activation of the Akt pathway abrogated Dex-induced osteocyte apoptosis. Significantly, we further found alterations in Akt signaling in clinical SAON samples. The modulation of Akt by GCs is a cell autonomous mechanism of Wnt/β-catenin antagonism that contributes to the adverse effects of excess GCs. Akt attenuation promotes the binding of β-catenin to FoxOs and inhibition of β-catenin/TCF activity (43) .
PTH counteracts the adverse effect of GCs by abrogating the suppressive effect of GCs on Akt phosphorylation and the Wnt pathway (46) . Moreover, inhibition of Akt-mTORC1 signaling by GCs induces autophagy, resulting in connexin 43 degradation and subsequently impairing osteocyte This article is protected by copyright. All rights reserved 16 cell-cell communication (20) . Interestingly, knockdown of TET3 in vitro can block the Akt activity inhibition induced by Dex. Thus, our data for the first time indicate that Dex-induced Akt pathway suppression is mediated by TET3.
In addition to Akt pathway-associated genes, GC-induced TET3-5hmC changes regulate the expression of a large number of genes, such as Notch, Dkk1 and Dkk4 (data not shown). Notch signaling plays a critical role in osteoblast cell fate and function, and endothelial Notch activity promotes angiogenesis and osteogenesis (47) . Dkk1 is involved in the inhibition of the Wnt signaling pathway, and its expression is associated with osteocyte apoptosis in SAON patients (48) . Bose et al. reported that TET3 mediates stable GC-induced alterations in DNA methylation and Dkk1 expression in neural progenitors (32) . This indicates that not only the Akt pathway but also other target genes may mediate the functional effect of GC-induced TET3-5hmC change and could be further explored.
Then, we found that knockdown of TET3 with specific siRNA transfection, which has been used in many studies, could abrogate SAON in vivo (2, 25) . In another SAON rabbit model, the blockade of Src with specific siRNA was used as a novel therapeutic strategy to prevent destructive repair (2) .
In our study, the effective knockdown of TET3 in vitro confirmed the specific mouse TET3 siRNA sequence. Considering the fact that we used rats to establish an SAON model, a BLAST search was performed in GenBank to validate that the sequence was conserved and also specific for rats.
Meanwhile, the efficiency of TET3 knockdown in vivo was confirmed with a western blot assay of the entire femoral head bone tissue. Furthermore, with the aim of exploring whether knockdown of TET3 could prevent the development of SAON, we performed TET3 siRNA injection on the first and fifteenth day of SAON induction. Interestingly, knockdown of TET3 in vivo prevented
GC-induced osteocyte apoptosis, histopathology changes, trabeculae decline and high-intensity
This article is protected by copyright. All rights reserved 17 T2W1 MRI signals in rat femoral heads. Unfortunately, our in vivo transfection method could not ensure the specific knockdown of TET3 in osteocytes. Liang et al. developed CH6 aptamerfunctionalized lipid nanoparticles (LNPs) to encapsulate siRNA and boosted in vivo osteoblast-specific gene silencing (49) . To understand the exact function of TET3 in osteocytes, further osteocyte-specific deletion of TET3 with a corresponding aptamer delivery system is warranted.
In conclusion, the current results indicate that TET3-5hmC-Akt signaling is critical for GC-induced osteocyte apoptosis and SAON and uncover a new mechanism of SAON. This finding indicates that inhibition of TET3 expression in osteocytes might be a new strategy to treat SAON early.
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